Magnetic Ganoderma Lucidum Spores (mGLS): A Novel Regulatable Targeted Drug Delivery System
Abstract In the past decades, many materials have been studied as carriers for targeted drug delivery. However, there is a need for utilizable and selective carrier materials with few side effects. Here, the magnetic Ganoderma Lucidum Spores (mGLS) as a highly efficient targeted drug delivery carrier were explored. Then the regulatable targeted drug delivery system was verified by loading and releasing of the 5-Fluorouracil (5-FU). The results showed that the maximum of the loaded 5-FU reached 250.23 mg·$ g^{−1} $ in the mGLS. The cumulative release of the 5-FU for the drug delivery system could reach 80.11% and 67.14% in the PBS and HCl after 48 h, respectively. In addition, this system showed the good pharmacokinetic properties in vivo. After 12 h, the blood concentration in the 5-FUmGLS group kept at 5.3 µg·$ mL^{−1} $ and was four times higher than that in the 5-FU group. In summary, the GLS as a natural microscale core-shell structures appears the striking application in carrier material for oral drug delivery..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Journal of bionic engineering - 18(2021), 4 vom: Juli, Seite 915-926 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Han, Bin [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
5-FU |
---|
Anmerkungen: |
© Jilin University 2021 |
---|
doi: |
10.1007/s42235-021-0059-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR044737785 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR044737785 | ||
003 | DE-627 | ||
005 | 20230519150737.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210804s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s42235-021-0059-2 |2 doi | |
035 | |a (DE-627)SPR044737785 | ||
035 | |a (SPR)s42235-021-0059-2-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Han, Bin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Magnetic Ganoderma Lucidum Spores (mGLS): A Novel Regulatable Targeted Drug Delivery System |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Jilin University 2021 | ||
520 | |a Abstract In the past decades, many materials have been studied as carriers for targeted drug delivery. However, there is a need for utilizable and selective carrier materials with few side effects. Here, the magnetic Ganoderma Lucidum Spores (mGLS) as a highly efficient targeted drug delivery carrier were explored. Then the regulatable targeted drug delivery system was verified by loading and releasing of the 5-Fluorouracil (5-FU). The results showed that the maximum of the loaded 5-FU reached 250.23 mg·$ g^{−1} $ in the mGLS. The cumulative release of the 5-FU for the drug delivery system could reach 80.11% and 67.14% in the PBS and HCl after 48 h, respectively. In addition, this system showed the good pharmacokinetic properties in vivo. After 12 h, the blood concentration in the 5-FUmGLS group kept at 5.3 µg·$ mL^{−1} $ and was four times higher than that in the 5-FU group. In summary, the GLS as a natural microscale core-shell structures appears the striking application in carrier material for oral drug delivery. | ||
650 | 4 | |a Magnetic Ganoderma Lucidum Spores (mGLS) |7 (dpeaa)DE-He213 | |
650 | 4 | |a sustained release |7 (dpeaa)DE-He213 | |
650 | 4 | |a 5-FU |7 (dpeaa)DE-He213 | |
650 | 4 | |a drug delivery |7 (dpeaa)DE-He213 | |
700 | 1 | |a Weng, Zhankun |4 aut | |
700 | 1 | |a Wu, Yuhan |4 aut | |
700 | 1 | |a Zhao, Xin |4 aut | |
700 | 1 | |a Li, Jingmei |4 aut | |
700 | 1 | |a Zhang, Qinhan |4 aut | |
700 | 1 | |a Qu, Kaige |4 aut | |
700 | 1 | |a Liang, Bojian |4 aut | |
700 | 1 | |a Zhou, Fenguo |4 aut | |
700 | 1 | |a Liu, Guixia |4 aut | |
700 | 1 | |a Wang, Zuobin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of bionic engineering |d Cham : Springer International Publishing, 2004 |g 18(2021), 4 vom: Juli, Seite 915-926 |w (DE-627)SPR038455234 |w (DE-600)2233712-X |x 2543-2141 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2021 |g number:4 |g month:07 |g pages:915-926 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s42235-021-0059-2 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 18 |j 2021 |e 4 |c 07 |h 915-926 |